RECURSION PHARMACEUTICALS, INC.

Listed Company

RXRXCIK 0001601830NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$74.68M

Net Income

$-644.76M

Total Assets

$1.47B

Equity

$1.13B

Shares Out

530.63M

Op. Cash Flow

$-371.81M

RXRX$2.94−46.64% · past yearDBEQ Basic

Daily closing prices

Business

Recursion Pharmaceuticals is a clinical-stage TechBio company that develops medicines using its integrated AI-native drug discovery and development platform, the Recursion Operating System (OS). The company advances a portfolio of internal drug candidates and strategic partnerships across oncology and rare disease, leveraging proprietary multimodal biological data, AI-powered molecular design, and automated clinical development. Recursion operates globally with wholly-owned programs in clinical development and partnerships with leading biopharmaceutical companies including Roche, Genentech, Sanofi, Bayer, and Merck KGaA.

Summary from 10-K filed 2026-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	75	59	45	40	10
Cost of revenue	71	45	43	48	0
Research and development	475	314	241	156	135
General and administrative	177	178	111	82	58
Total operating costs and expenses	723	538	395	286	193
Loss from operations	−648	−479	−350	−246	−183
Other income, net	3	14	18	6	−4
Loss before income tax benefit	−645	−465	−332	−239	−186
Income tax benefit	136,000	1	4	0	0
Net loss	−645	−464	−328	−239	−186
Net loss per share of class A, B and exchangeable common stock, basic (in dollars per share)	−1.44	−1.69	−1.58	−1.36	−1.49
Net loss per share of class A, B and exchangeable common stock, diluted (in dollars per share)	−1.44	−1.69	−1.58	−1.36	−1.49
Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares)	447	274	208	176	125
Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares)	447	274	208	176	125

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	743	594	392	550	285
Restricted cash	5	3	3	1	2
Other receivables	25	49	3	3	9
Prepaid data assets	12	30	—	—	—
Other current assets	29	38	40	16	8
Total current assets	813	714	438	570	535
Restricted cash, non-current	6	6	7	8	9
Property and equipment, net	104	141	87	88	65
Operating lease right-of-use assets	45	66	34	33	33
Financing lease right-of-use assets	20	26	0	—	—
Intangible assets, net	310	336	36	1	1
Goodwill	162	149	52	801,000	801,000
Deferred tax assets	957,000	2	0	—	—
Other assets, non-current	13	9	261,000	0	35,000
Total assets	1,474	1,449	654	701	610
Accounts payable	18	22	4	5	3
Accrued expenses and other liabilities	70	82	47	33	32
Unearned revenue	38	62	36	57	10
Operating lease liabilities	13	14	6	6	0
Notes payable and financing lease liabilities	9	8	41,000	—	—
Total current liabilities	148	187	93	100	47
Unearned revenue, non-current	114	119	51	70	7
Operating lease liabilities, non-current	47	67	43	44	0
Notes payable and financing lease liabilities, non-current	10	19	1	—	—
Deferred tax liabilities	23	17	1	0	—
Other liabilities, non-current	2	5	0	—	—
Total liabilities	343	414	190	215	67
Commitments and contingencies (Note 7)	—	—	—	—	—
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of December 31, 2025 and December 31, 2024; 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) and 396,802,394 (Class A 389,547,223 and Class B 6,958,575 and Exchangeable 296,596) issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	5,000	4,000	2,000	2,000	2,000
Additional paid-in capital	3,170	2,474	1,431	1,125	943
Accumulated deficit	−2,100	−1,431	−968	−640	−400
Accumulated other comprehensive income (loss)	37	−8	0	0	−126,000
Total stockholders equity	1,131	1,035	463	486	543
Total liabilities and stockholders equity	1,474	1,449	654	701	610

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	84	36	24	12	8
Stock-based compensation	111	82	54	28	15
Asset impairment	6	108,000	1	3	0
Lease expense	22	17	8	8	0
Loss on disposal of a business	5	0	0	—	—
Acquired IPR&D	22	0	0	—	—
Other, net	10	16	−3	830,000	4
Other receivables and assets	33	−6	−8	−2,000	−5
Prepaid data assets	50	−9	6	—	—
Unearned revenue	−37	−28	−41	110	−10
Accounts payable	−3	6	−987,000	2	2
Accrued development expense	−2	−264,000	3	522,000	561,000
Accrued expenses and other current liabilities	−7	6	7	−576,000	13
Lease liabilities	−20	−16	−10	−7	—
Net cash used in operating activities	−372	−359	−288	−84	−159
Net cash acquired in the acquisition of a business	0	277	2	0	0
Purchases of property and equipment	−6	−14	−12	−37	−40
Purchases of intangible assets	−2	−3	−597,000	−300,000	0
Decrease in cash related to disposal of a business	−4	0	0	—	—
Purchases of investments	−4	0	0	—	—
Sales and maturities of investments	0	0	480,000	231	—
Net cash provided by (used in) investing activities	−17	260	−10	193	−272
Proceeds from issuance of common shares, net of issuance costs	529	300	128	144	463
Proceeds from equity incentive plans	4	8	13	11	8
Repayment of long-term debt and finance lease liabilities	−8	−4	−766,000	−90,000	—
Purchase of an intangible asset	−3	0	0	—	—
Net cash provided by financing activities	522	304	140	154	459
Effect of exchange rate changes on cash, cash equivalents and restricted cash	18	−3	188,000	−307,000	0
Net change in cash, cash equivalents and restricted cash	151	202	−158	264	28
Issuance of shares for the acquisitions of businesses and agreement	20	630	89	0	0
Accrued property and equipment	0	439,000	2	591,000	8
Purchase of an intangible asset	0	6	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is RECURSION PHARMACEUTICALS, INC.'s CIK number?

RECURSION PHARMACEUTICALS, INC.'s SEC CIK number is 0001601830 (1601830). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find RECURSION PHARMACEUTICALS, INC.'s SEC filings?

All of RECURSION PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did RECURSION PHARMACEUTICALS, INC. last report earnings?

RECURSION PHARMACEUTICALS, INC. (RXRX) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001601830-26-000077). This is RECURSION PHARMACEUTICALS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is RECURSION PHARMACEUTICALS, INC.'s most recent earnings 8-K?

RECURSION PHARMACEUTICALS, INC.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001601830-26-000077. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View RECURSION PHARMACEUTICALS, INC.'s latest earnings 8-K →
Look up any company's CIK number →